Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission

1

Hoth Therapeutics is utilizing AI to advance its investigational targeted therapy HT-KIT for KIT-driven cancers.
2

The AI platform aids in data analysis, cancer pathway modeling, and regulatory documentation for IND submission.
3

HT-KIT targets rare cancers driven by KIT mutations, including systemic mastocytosis and gastrointestinal stromal tumors.
4

Preclinical studies show HT-KIT achieved over 80% reduction in KIT mRNA and protein expression in cancer models.
5

Safety data from preclinical studies indicate no dose-limiting toxicities, supporting the candidate's progression to phase I.

1